EWTX · CIK 0001710072 · operating
Edgewise Therapeutics is a biopharmaceutical company focused on discovering and developing therapies for muscle disorders. The company's lead program, EDG-5506, is an orally administered small molecule candidate currently in Phase II clinical trials designed to treat dystrophinopathies, including Duchenne and Becker muscular dystrophy, by addressing underlying disease mechanisms. The company also develops EDG-7500, a small molecule in Phase I trials for hypertrophic cardiomyopathy and other severe cardiac conditions, alongside a pipeline of precision medicine candidates targeting genetically defined muscle disorders through modulation of key muscle proteins.
As a clinical-stage biopharmaceutical company, Edgewise does not currently generate revenue from approved therapeutics. The company operates from its headquarters in Boulder, Colorado, with a workforce of 136 full-time employees. Incorporated in Delaware in 2017, the company is publicly listed on the Nasdaq with a market capitalization of $3.2 billion.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-1.63 | $-1.63 | -12.4% | |
| 2024 | $-1.45 | $-1.45 | +7.6% | |
| 2023 | $-1.57 | $-1.57 | -24.6% | |
| 2022 | $-1.26 | $-1.26 | -10.5% | |
| 2021 | $-1.14 | $-1.14 | — |